These may include hormonal imbalances, liver strain, cardiovascular issues, psychological effects, and more
Give it a read
Moreover, given that there are now millions of patient-years of clinical experience with DPP-4 inhibitors since they were given regulatory approval in 2006, their benign, placebo-like side effect profile (39) also suggests that the number of physiologically relevant substrates is likely to be limited
This collaborative approach ensures that all aspects of your medical history are considered and appropriate monitoring arrangements are established
Heffron and his colleagues also conducted a subgroup analysis, collecting trials that compared GLP-1 agonists with DPP-4 inhibitors (an older class of diabetes medications), both of which raise blood levels of GLP-1
It may be more prominent if you are using it for the first time